Funding will enhance Molecular Staging’s leadership position in signal and target amplification and accelerate MSI’s efforts in the proteomics, genomics and molecular diagnostics markets.

NEW HAVEN, CT — Molecular Staging Inc. (MSI), a privately-held life sciences tool company, announced today that it has completed a Series D preferred stock financing totaling $41.25 million. Investor AB, through Investor Growth Capital, participated in the private placement along with OrbiMed, CIBC Capital Partners and Cooper Hill Partners. Domain Partners III, CHL Medical Partners and 3i Bioscience Investment Trust, who were already holders of preferred stock in Molecular Staging, also participated in the new round of financing. Investor AB and OrbiMed will be entitled to name two representatives to the board.

Liza Page Nelson, Managing Director of Investor Growth Capital said “Molecular Staging has made tremendous progress in the development and validation of its key platforms. Seldom does one find a company whose technology can broadly address so many markets; these include research reagents, drug research and development, diagnostics, and life sciences.”
Read the rest of this entry »

Ultra-sensitive Prototype Assay for Prostate Cancer Marker Also Reported
PRINCETON, N.J., Oct. 2 /PRNewswire/ — AxCell Biosciences Corporation, a subsidiary of Cytogen Corporation (Nasdaq: CYTO - news) and Molecular Staging, Inc., (MSI), Guilford, CT, initiated a scientific plan to investigate potential synergies between their technologies to map protein pathways more rapidly and efficiently. MSI’s Rolling Circle Amplification Technology (RCATTM) is a proprietary, highly sensitive and efficient amplification method for detecting the presence of target molecules micro-arrayed on a biochip. By combining AxCell’s domain-ligand interaction technology with MSI’s protein arrays, the two companies believe that they may be able to increase the rate of protein interaction measurements by 10 fold more than AxCell’s current rate of approximately 10,000 interactions per day.
Read the rest of this entry »

PRINCETON, N.J., Sept. 28 /PRNewswire/ — Cytogen Corporation (Nasdaq: CYTO) announced today that it had signed a letter of intent to obtain an exclusive, worldwide license from Molecular Staging, Inc. (MSI) of Guilford, CT, for their novel Rolling Circle Amplification Technology (RCAT) to develop in vitro diagnostic tests for Prostate Specific Membrane Antigen (PSMA) and Prostate-Specific Antigen (PSA).

Serum PSA testing has revolutionized the diagnosis and management of prostate cancer and several million tests are done every year in the United States to screen for malignancy. It is estimated that over $400 million is now spent on PSA testing. However, in two-thirds of men with an elevated PSA the cause is something other than cancer, so the patient is caused needless anxiety and subjected to unnecessary investigation.
Read the rest of this entry »

The Anglo-Swedish company Amersham Pharmacia Biotech has signed an exclusive deal to develop a rival technology to PCR (Polymerase Chain Reaction), which has become one of the fundamental tools of molecular biology.

PCR was invented by Californian scientist Kary Mullis, and won him a share of the Nobel Prize for Chemistry in 1993.
Read the rest of this entry »

NEW HAVEN, April 18, 2002/– Molecular Staging Inc. (MSI) today announced the publication of a landmark paper in this month’s issue of Nature Biotechnology that describes a new approach to analyzing multiple proteins simultaneously on a glass chip microarray.

The paper, entitled “Multiplexed Protein Profiling on Microarrays using Rolling Circle Amplification (RCAT),” describes a chip based proteomics discovery platform that employs RCAT to amplify signals from proteins in a highly multiplexed format.
Read the rest of this entry »

NEW
HAVEN, April 16, 2002/– Molecular Staging Inc.
(MSI) today announced the publication of a paper in
today’s issue of Proceedings of the National Academy of
Sciences of the United States of America (PNAS) that
describes a method for generating millions of DNA copies
from just a few cells.

Read the rest of this entry »

NEW HAVEN, April 4, 2002/– Molecular Staging Inc. (MSI) today announced that it has been awarded three additional patents for Rolling Circle Amplification Technology (RCATTM). MSI now has a total of fourteen issued patents in the U.S., Europe and Australia covering this technology and its applications.
Read the rest of this entry »

NEW HAVEN, CT, December 11, 2001 - Molecular Staging Inc. (“MSI”) today announced publication of a paper in the November issue of Nucleic Acids Research that describes the application of the Company’s proprietary Rolling Circle Amplification Technology (RCATTM) to detect nucleic acids on microarrays.
Read the rest of this entry »

NEW HAVEN, CT., October 30, 2001/– Molecular Staging Inc. (MSI) today announced a published abstract in the October 2001 issue of Clinical Chemistry. The abstract described the application its of MSI’s Rolling Circle Amplification TechnologyTM (RCATTM) for the detection of allergen-specific IgE, the antibody in patient serum used to predict an allergic response in individuals with concordant clinical history.
Read the rest of this entry »

NEW HAVEN, October 8, 2001 /– Molecular Staging Inc. (MSI) announced today that it received a Small Business Innovative Research (SBIR) grant to develop a method of detecting rare Human Papillomavirus (HPV) transformed cells using Rolling Circle Amplification Technology (RCATTM).
Read the rest of this entry »